Plasma levels of heparin cofactor II (HCII) and thrombin-HCII complex in patients with disseminated intravascular coagulation

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 3, 2002, Pages 265-271

  Noda, Ayako ^a   Wada, Hideo ^a   Kusiya, Fumihiko ^a   Sakakura, Miho ^a   Onishi, Katsuya ^a   Nakatani, Kaname ^a   Gabazza, Esteban C ^a   Asahara, Naomi ^b   Tsukada, Minoru ^b   Nobori, Tsutomu ^a   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitsubishi Phanua Corporation   (Japan)

Author keywords

DIC; Heparin cofactor II; Heparin cofactor II complex; Infection; Thrombin

Indexed keywords

ANTITHROMBIN; D DIMER; HEPARIN COFACTOR II; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN HEPARIN COFACTOR COMPLEX II; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOGENESIS;

ANTITHROMBIN III; CASE-CONTROL STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; HEPARIN COFACTOR II; HUMANS; INFECTION; NEOPLASMS; PEPTIDE HYDROLASES; PROTEIN BINDING; THROMBIN;

EID: 0036658149     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800311     Document Type: Article

References (20)

1. Bick RL. Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemost 1998;14:299.
2. Muller-Berghaus G. Pathophysiologic and biochemical events in desseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989;15:58.
3. Buller HR, ten Cate JW. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med 1989;87(Suppl. 3B):44S.
4. Mammen EF, Miyakawa T, Murano G, et al. Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin Thromb Haemost 1985; 11:373.
5. Okugawa Y, Wada H, Noda N, et al. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complexes in patients with disseminated intravascular coagulation. Am J Hematol 2000;65:210.
6. Wada H, Gabazza E, Nakasaki T, et al. Diagnosis of disseminated intravascular coagulation by hemostatic molecular markers. Semin Thromb Hemost 2000;26:17.
7. Roman K, Rosenthal E, Razavi R. Pulmonary arterial thrombosis in a neonate with homozygous deficiency of antithrombin III: Successful outcome following pulmonary thrombectomy and infusions of antithrombin III concentrate. Cardiol Young 2000;10:275.
8. Matsuo T, Kario K, Sakamoto S, et al. Hereditary heparin cofactor II deficiency and coronary artery diseases. Thromb Res 1992;65:495.
9. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982;257:2162.
10. Anderson TR, Sie P, Pelzer H, et al. Elevated levels of thrombi-heparin cofactor II complex in plasma from patients with disseminated intravascular coagulation. Thromb Res 1992;66:591.
11. Smith D. Report of the International Meetig on Intensive Care Medicine, Rome, Italy, October 1-4, 2000. Crit Care 2000;4:255.
12. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety for recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699.
13. Kobayashi N, Maegawa K, Takada M, et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1987;49:265.
14. Wada H, Minamikawa K, Wakita Y, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1993;44:85.
15. Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost 1998; 24:293.
16. Nielsen JD. The effect of antithrombin on the systemic inflammatory response in disseminated intravascular coagulation. Blood Coagul Fibrinol 1998;9(suppl 3):S11.
17. Waydhas C, Nast-Kolb D, Gippner-Steppert C, et al. High- dose antithrombin III treatment of severely injured patients: Results of a prospective study. J Trauma 1998;45: 931.
18. Esmon C. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51.
19. Kario K, Matsuo T, Kodama K, et al. Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyclocytic leukemia. Thromb Res 1992;66:435.
20. McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. J Biol Chem 1987;262:169.